Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Gains from Investment Securities (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Gains from Investment Securities for 6 consecutive years, with -$7.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 686.17% year-over-year to -$7.2 million, compared with a TTM value of $50000.0 through Dec 2025, down 65.99%, and an annual FY2025 reading of $50000.0, down 65.99% over the prior year.
  • Gains from Investment Securities was -$7.2 million for Q4 2025 at Viemed Healthcare, down from $208000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.5 million in Q2 2025 and bottomed at -$7.2 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $103823.5, with a median of $208000.0 recorded in 2025.
  • The sharpest move saw Gains from Investment Securities skyrocketed 1712.93% in 2022, then plummeted 686.17% in 2025.
  • Year by year, Gains from Investment Securities stood at $1.5 million in 2021, then plummeted by 214.65% to -$1.8 million in 2022, then surged by 153.35% to $948000.0 in 2023, then tumbled by 196.84% to -$918000.0 in 2024, then tumbled by 686.17% to -$7.2 million in 2025.
  • Business Quant data shows Gains from Investment Securities for VMD at -$7.2 million in Q4 2025, $208000.0 in Q3 2025, and $5.5 million in Q2 2025.